Sema4
Avera Health, Sema4 Launch Five-Year Precision Oncology Study
The health system and the bioinformatics firm will sequence and provide PGx testing for as many as 15,000 patients in hopes of targeting cancer prevention and treatments.
Sema4 to Study Precision Oncology Disparities in Nationwide Biobanking, Genomic Profiling Study
The firm will use its suite of assays to characterize samples from 5,000 advanced cancer patients from underserved communities and create a representative biobank.
Sema4, Avera Health Collaborate on Precision Oncology Program
The partnership, which will start with oncology, will introduce Sema4's genomic testing and Centrellis health intelligence technology to Avera's clinical and research programs.
In Brief This Week: Eli Lilly, Mirati Therapeutics, Legend Biotech, Personal Genome Diagnostics, Sema4
News items for the week of June 21, 2021.
JP Morgan Healthcare, Day 2: Eli Lilly, Pfizer, GlaxoSmithKline, Clovis Oncology, Invitae, and More
Verzenio, Ibrance, Rubraca, and bintrafusp alfa are some of the precision oncology products companies provided updates on during the conference.